Compare Quest Diagnostics Inc (DGX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Royal Caribbean Cruises Ltd — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Royal Caribbean Cruises Ltd trades at $294.9 (market cap $75.92B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 3.3× Quest Diagnostics Inc's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| DGX | RCL | |
|---|---|---|
Market Cap | $22.80B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $365.84 |
52-Week Low | $166.42 | $246.71 |
Enterprise Value | $28.82B | $97.20B |
Dividend Yield | 1.67% | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Royal Caribbean (RCL) trades at $288.61, up 1.14% today, with a bullish technical setup near key resistance at $292. The company demonstrates strong fundamental momentum, with 2025 revenue reaching $17.93 billion and net income surging to $4.27 billion, yielding a robust 24.36% net margin. Analyst consensus is positive, with a $328 price target implying 14% upside, supported by 25 buy ratings. Recent news highlights Caribbean demand strength offsetting European softness, with Q2 2026 earnings due July 28.
RCL's outlook is favorable, driven by earnings beats, expanding margins, and strategic destination investments. Key risks include Europe demand volatility, high debt levels, and competitive pressures. Institutional sentiment leans bullish, but macroeconomic sensitivity and execution on yield growth remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
